Caveolin-1 Expression Level in Cancer Associated Fibroblasts Predicts Outcome in Gastric Cancer

Xianda Zhao1, Yuyu He1,3, Jun Gao2, Lifang Fan1, Zonghuan Li1, Guifang Yang3, Honglei Chen1,4*

1 Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan, P. R. China, 2 Department of Molecular Pathology, Wuhan Nano Tumor Diagnosis Engineering Research Center, Wuhan, P. R. China, 3 Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, P. R. China, 4 Department of Biochemistry, Rush University Medical Center, Chicago, Illinois, United States of America

Abstract

Aims: Altered expression of epithelial or stromal caveolin-1 (Cav-1) is observed in various types of human cancers. However, the clinical significance of Cav-1 expression in gastric cancer (GC) remains largely unknown. The present study aims to explore the clinicopathological significance and prognostic value of both tumor cells and cancer associated fibroblasts (CAFs) Cav-1 in GC.

Methods and Results: Quantum dots immunofluorescence histochemistry was performed to examine the expression of Cav-1 in 20 cases of gastritis without intestinal metaplasia (IM), 20 cases of gastritis with IM and 286 cases of GC. Positive rates of epithelial Cav-1 in gastritis without IM, gastritis with IM and GC showed a decreasing trend (P = 0.012). Low expression of Cav-1 in CAFs but not in tumor cells was an independent predictor of poor prognosis in GC patients (P = 0.034 and 0.005 respectively in disease free survival and overall survival). Cav-1 level in tumor cells and CAFs showed no significant correlation with classic clinicopathological features.

Conclusions: Loss of epithelial Cav-1 may promote malignant progression and low CAFs Cav-1 level herald worse outcome of GC patient, suggesting CAFs Cav-1 may be a candidate therapeutic target and a useful prognostic marker of GC.

Introduction

Like normal tissues, tumors are composed of two discrete but interactive compartments, the parenchyma and the stroma. In tumors, the tumor cells themselves are parenchyma, whereas the stroma includes a mixture of extracellular matrix (ECM) elements and non-malignant cells, such as cancer associated fibroblasts (CAFs), vascular endothelial cells and immune and inflammatory cells [1,2,3]. In recent years, the profound influences of tumor stroma on the growth and metastasis in various types of tumors have been widely elucidated [2,3]. Tumor cells can trigger the deposition of a reactive stroma containing activated CAFs, immune and inflammatory cells, ECM elements that may favor invasion and metastasis of cancers [2,3]. Besides, although definite roles of proteins in molecular cross talk between tumor and stromal cell remain unclear, altered expression of stromal proteins have been manifested as novel biomarkers in various types of human cancers, including breast [4,5,6,7], prostate [8], nasopharynx [9] and basal cell cancer [10].

The caveolin gene family has three members: CAV1, CAV2, and CAV3, coding for the proteins caveolin-1 (Cav-1), caveolin-2 and caveolin-3, respectively [11]. CAV1 is located on chromosome 7 (locus 7q31.1) and contains three exons (35, 165 and 324 bp) and two introns (1.5 and 32 kb) [11]. Cav-1 constitutes the major structural component of caveolae, which are flask-shaped vesicular invaginations of plasma membrane [12,13]. Various receptors and signaling molecules are localized in the caveolae and are negatively regulated by Cav-1 through its scaffolding domain. Besides, Cav-1 interacts directly with the bilayer of cholesterol and sphingolipids within caveolin, therefore, influencing the lipid homeostasis and transport [12,13]. In cancers, it is increasingly clear that Cav-1 is implicated in regulating multiple cancer-associated processes, ranging from cellular transformation, tumor growth, invasion and metastasis, to multidrug resistance and angiogenesis [14]. Cav-1 shows a compartment-dependent role on tumors. In the epithelial compartment, Cav-1 impacts both positively and negatively on tumor development. In tumor stroma, especially the CAFs, low expression of Cav-1 protein predicts adverse outcome in breast and prostate cancer [4,5,6,8,12,15]. Nevertheless, clinical values of Cav-1 in GC remain not entirely clear. Based on prior researches, we hypothesis that roles of Cav-1 in epithelial and stroma may be different, roles of epithelial Cav-1 is uncertain but low expression of Cav-1 in CAFs may promotes GC progression and correlates with adverse outcome of GC patients.
To clarify the relationship between Cav-1 and GC progression or suppression, we have analyzed specifically both stromal and epithelial cell expression of Cav-1 in tissues sections, via the advanced quantum dots (QDs)-based immunofluorescence histochemistry (QDs-IHC) that had been developed in our previous studies and which have been widely accredited and used in laboratories [16,17,18,19,20,21,22]. Fluorescent semiconductor nanocrystal QDs are a novel class of multifunctional inorganic fluorophores that have many benefiting properties, such as narrow emission band peaks, wavelength of their fluorescence depends strongly on their sizes and different QD colors can be simultaneously excited by a single light source with minimal spectral overlapping [16,17,18,19,20,21,22]. These properties make QDs extremely useful for multiplexed molecular immunofluorescent imaging [21,23]. The advanced multiple targets labeling technology of QDs-IHC enabled a precise analysis of Cav-1 expression in GC and our feasibility experiment indicated that expression in one set of TMAs. The most representative tumor areas were defined on hematoxylin- and eosin-stained sections and marked on the slide. The way we constructed the TMAs and the microarray system instrument set contained 5 TMAs that were mounted with 340 specimens. The most representative tumor areas were defined on hematoxylin- and eosin-stained sections and marked on the slide. The way we constructed the TMAs and the microarray system instrument set contained 5 TMAs that were mounted with 340 specimens.

**Materials and Methods**

**Patients and Follow-up**

Because the time was limited and some patients were out of the hospital, so it is difficult to obtain written consent. We called to each patient, explained our study was used for academic exchanges only, and was not harmful to their health, and not contained their private information. When we called, a notary public was present, and we received the mobile phone short message which we required patients who consent the study to send to us. If the patient has dead, we got consent from his or her legal representative. Finally, we obtained verbal consent from all the 300 patients. A total of 340 formalin-fixed, paraffin-embedded tissues were obtained from patients diagnosed in the period from July 2005 to February 2012, including 300 GCs, 20 gastritis without intestinal metaplasia (IM) tissues and 20 gastritis with IM tissues. The gastritis without IM and with IM samples were derived from adenocarcinoma paracancerous tissues. Serial section confirmed no tumor tissue was found in these samples. Specimens were collected from the archives of the Department of Pathology, Zhongnan Hospital of Wuhan University (Hubei, P.R. China). Histological diagnosis and grades of differentiation were determined in accordance with the World Health Organization (WHO) criteria for GC. All of the GC samples were classified based on the UICC TNM classification (2009). Two board-certified pathologists (Yang GF and Fan LF) reconfirmed the histopathologic features of these samples. 326 samples were successfully preserved for further analysis; meanwhile, 14 GC samples were lost from the slide during immunostaining. Clinicopathological factors of GC patients were listed in Table 1. All these 300 patients were treated with radical resection or cytotherapeutic surgery of GC, prior to administration of chemotherapy or radiotherapy. This study was approved by the Institute Research Medical Ethics Committee of School of Basic Medical Science, Wuhan University.

Follow-up began on the date of surgery and ended in August 2012. Among the remaining 286 GC tissues from patients, 257 enrolled in our follow-up cohort and 116 patients who successfully reached a five year follow-up or died because of GC were included in the survival analysis. Patients, who did not reach five year follow-up and died of other diseases or due to unexpected events, were excluded from the survival study. The median follow-up of the 116 patients was 62 (range: 1–85) months. Overall survival was defined as the interval from the date of surgery to death. Disease free survival was defined as the interval from the date of surgery to recurrence. Diagnosis of recurrence was based on the following criteria: local recurrence found by endoscopic biopsy or with relaparotomy; metastasis on radiological, ultrasonic or cytological examination.

**Tissue Microarray Construction**

Two sets of tissue microarrays (TMAs) were constructed. Each set contained 5 TMAs that were mounted with 340 specimens. The most representative tumor areas were defined on hematoxylin- and eosin-stained sections and marked on the slide. The way we constructed the TMAs and the microarray system instrument were the same with our previous study [24,25]. As previously studies did not report intratumoral heterogeneity of Cav-1 expression in GC and our feasibility experiment indicated that one core per tumor on TMA and large sections showed a good consistency [26,27,28], therefore, in testing experiment, one core was sampled in each case. Briefly, one core with a diameter of 1.5 mm was taken from each sample and inserted into empty 1.5 mm thick) and used for QDs-IHC analysis.

**QDs-based Immunofluorescence Histochemistry**

Cav-1 immunoreactivity was detected in one set of TMAs. The antibodies, QDs conjugated streptavidin probes (QDs-SA) with 605 nm emission wavelength and related reagents for Cav-1 detection were the same as before [16] with the following major procedures: deparaffinizing → antigen retrieval → blocking → primary antibody for Cav-1(Cell Signaling Technology, Beverly,

---

**Table 1. Patient characteristics (N=286).**

| Characteristic          | Sub-characteristic | Value |
|-------------------------|--------------------|-------|
| Age(year)               |                    | 57(24–92) |
| Gender                  | Male               | 205   |
|                         | Female             | 81    |
| UICC stage             | Ia/Ib              | 8/51  |
|                         | II                 | 83    |
|                         | IIIa/IIIb          | 105/34 |
|                         | IV                 | 5     |
| Pathologic type        | AC                 | 237   |
|                         | Mucinous AC        | 32    |
|                         | UC                 | 17    |
| Grade of AC            | I                  | 8     |
|                         | II                 | 70    |
|                         | III                | 159   |
| Lymph node status      | No                 | 113   |
|                         | Yes                | 173   |
| HER 2 statues          | Positive           | 34    |
|                         | Negative           | 145   |
|                         | Unknown            | 107   |
| Lauren classification  | Intestinal-type    | 137   |
|                         | Diffuse-type       | 123   |
|                         | Mixed-type         | 26    |

**Notes:**

- TNM classification of malignant tumors (7th edition).
- AC: Adenocarcinoma; UC: Undifferentiated carcinoma.
- doi:10.1371/journal.pone.0059102.t001
MA) → washing and blocking → biotinylated IgG → washing and blocking →605 nm-QDs-SA → washing → mounting and observation. The signal obtained from the labeling cells was detected via using Olympus BX51 fluorescence microscopy (CCD DP72). The QDs signal was target specific, red, and photostable. Autofluorescence of tissue-background was green. Since Cav-1 normally localizes in endothelial cells of blood vessels [27,29] that examined in every TMA, it can be served as internal positive and quality control in QDs-IHC. TBS instead of Cav-1 primary antibody served as negative control.

QDs-based Double Immunofluorescent Labeling

We used one set of TMAs for Cav-1/α-SMA colocalization, detected by QDs-based double immunofluorescent labeling technology according to the manufacturer’s instructions (Wuhan Jiayuan Quantum Dots Co., Ltd.). All dilution steps (antibodies and QDs) were performed in TBS containing 2% bovine serum albumin (BSA, Sigma, St. Louis, MO, USA). Antigen retrieval was performed in citric acid (10 mM, pH 6.0) at 95°C for 10 min, followed by cooling for 30 min. TMAs were first incubated in 2% BSA buffer at 37°C for 30 min, and then at 4°C overnight in rabbit anti-Cav-1 polyclonal antibody and mouse anti-α-SMA monoclonal antibody (1:300 dilution, Abcam, Cambridge, MA) in order to antibody bindings. Then TMAs were washed three times with TBS-T (0.5% Tween in TBS) for 5 min each time, and incubated in biotinylated goat anti-mouse IgG (1:400 dilution, Jackson ImmunoResearch, West Grove, PA) at 37°C for 30 min. For QDs conjugation, the antibody-binding TMAs were incubated in 2% BSA buffer at 37°C for 10 min, incubated in QDs (525 nm) conjugated to streptavidin (1:200, Wuhan Jiayuan Quantum Dots Co., Ltd.) and QDs (605 nm) conjugated to goat anti-rabbit IgG (1:100, Wuhan Jiayuan Quantum Dots Co., Ltd.) for 50 min, rinsed three times with TBS-T for 5 min each. Finally, TMAs were sealed with 90% glycerin (Sigma). The immunofluorescent signal was observed by Caliper’s multispectral microscopy imaging systems (Caliper Life Sciences). Because the immunofluorescent signal of single labeling and double labeling were snapped by CCD DP72 and multispectral microscopy imaging systems respectively, we calibrated results of the two instruments to ensure comparability of these experiments. Positive signal of α-SMA was green, and Cav-1 was red. Cav-1 expression in endothelial cells of blood vessels [27,29], α-SMA expression in blood vessels and known positive tissue are regarded as the positive controls. TBS instead of two primary antibodies served as negative controls, only showing autofluorescence signal.

Scoring of the Immunofluorescent Results

Results were evaluated by two pathologists (Yang GF and Fan LF) simultaneously in same displayer, who are independent and blinded to the clinical features of the study. The scores of the two pathologists were compared and any discrepant scores were reassessed by reevaluation of the stained tissue specimen by the two pathologists to achieve a consensus score. The methodology for scoring Cav-1 staining of tumor cells and CAFs were the same. Scores were determined by combining the proportion of positively stained cells and the intensity of staining. The sections were initially scanned at low power. Then cells from five representative fields of each specimen at high magnification (200×) were counted for the score.
for Cav-1-stained tumor cells or CAFs. The area of positive (AP) are graded the cells as follows: 0 (no positive area or positive area <5%), 1 (positive area 5–25%), 2 (positive area 26–50%), 3 (positive area 51–75%) and 4 (positive area >75%). Cav-1 intensity of staining (IS) by the numerical value is resulted in scores: 0 (negative: no positive signal), 1 (weak: light or dark red signal) and 2 (strong: bright red signal). Expression levels of Cav-1 were calculated based on the total score as the following equation: Intensity distribution (ID) = AP × IS.

The cutoff value for high and low expression was determined on the receiver operating characteristic (ROC) curve analysis with the respect to overall survival. According to the optimal sensitivity and specificity of the ROC curve by overall survival status, 1.5 was defined as the optimal cutoff for Cav-1 immunofluorescent score in CAFs (an ID score ≥1.5 defined high expression and ID score <1.5 indicated low expression), 3.5 was defined as the optimal cutoff for Cav-1 immunofluorescent score in tumor cells (an ID score ≥3.5 defined high expression and ID score <3.5 indicated low expression).

Statistical Analysis

We used SPSS 17.0 software (Chicago, IL, USA) to carry out all statistical analyses. Friedman test was used to analyze the difference of Cav-1 original scores among different gastric lesions. ROC curve analysis was conducted to determine the cutoff point of high or low Cav-1 level and evaluate the predictive value of Cav-1 expression for overall survival. The x2 test or Fisher’s exact test was used to analyze the correlation between the clinicopathological parameters and Cav-1 expression. Spearman’s rank correlation test was performed to analyze the association between Cav-1 expression in tumor cells and CAFs. The overall survival and disease free survival rate were estimated using the Kaplan-Meier method and compared using the long-rank test. Multivariate analysis using Cox proportional hazard regression model was used to test independent prognosis values. Two tailed P-values <0.05 were considered statistically significant.

Results

Expression of Cav-1 in Different Gastric Lesions

The localization and expression of Cav-1 in gastritis without IM, gastritis with IM and GC were assessed by QDs-IHC using the Cav-1 polyclonal antibody. The strong intensity doughnut-shaped positive signal of Cav-1 in the tumour stroma was the internal control of endothelial expression (Fig. 1A). In gastritis without IM tissues, negative Cav-1 signal predominantly in the surface mucous cells (Fig. 1A) and positive signal predominantly in the base and neck of fundic gland cells (Fig. 1C). In gastritis with IM tissues, some cases showed no Cav-1 distribution (Fig. 1E) and some showed positive Cav-1 staining in the absorptive cell and goblet cell of metaplastic glands (Fig. 1G). Expression of Cav-1 immunoactivity was primarily observed at the cell membrane (Fig. 1L) and cytoplasm. The standard of signal scoring was displayed in Figure. 1I–K and representative examples of Cav-1 expression in GC were shown in Figure. 2. Colocalization of Cav-1 and α-SMA proteins was detected by QDs-based double immunofluorescent labeling in the GC, and analyzed by multispectral imaging systems, to precisely identify Cav-1 expression in CAFs (Fig. 3). The distribution of the signal of Cav-1 in fibroblasts is random and has no relation with the Cav-1 status in tumor cells.

Table 2 summarized the original scores of Cav-1 expression in gastritis without IM, gastritis with IM and GC. In endoscopic compartment, 30% (6/20) of gastritis without IM, 55% (11/20) of gastritis with IM, 75% (15/20) of GC were scored 0, showing Cav-1 protein expression level decreasing gradually. Friedman test showed that the difference of Cav-1 staining score between gastritis without IM, gastritis with IM and GC was statistically significant (P = 0.012).

Correlation Expression of Cav-1 between Tumor Cells and CAFs

Correlation between tumor cells and CAFs in Cav-1 expression was also analyzed. As was shown in Table 3, among 226 cases with low Cav-1 expression in tumor cells, 121 (53.5%) cases showed low expression of Cav-1 in CAFs (Fig. 2A), and among 21 cases with high Cav-1 expression in tumor cells, 9 (42.9%) cases displayed high Cav-1 expression in CAFs (Fig. 2C). The other 117 cases showed distinct expression status in tumor cell and CAFs (Fig. 2E and G). No significant correlation was founded between tumor cells and CAFs Cav-1 expression (r = −0.20, P = 0.751).

Clinical Significance of Cav-1 Expression in Tumor Cells and CAFs of GC

All 286 GC samples were available for analysis of Cav-1 immunostaining in tumor cells and 247 (86.4%) cases had sufficient tissues for analysis of Cav-1 immunostaining in CAFs. Table 3 summarized the correlation between tumor cells or CAFs Cav-1 expression and the classic clinicopathological parameters of GC, such as age, gender, T stage and lymph node status in univariate analysis. However, no significant relationship was found.

Furthermore, we investigated the diagnostic value of Cav-1 expression in tumor cells and CAFs. Kaplan-Meier analysis and the log-rank test showed that low expression of Cav-1 in CAFs rather than in tumor cells predicted poor survival. Median overall survival of low Cav-1 expression subgroup was 73.0 months (95% CI, 55.589–90.411), while in the follow-up interval, the high Cav-1 expression subgroup had a calculated survival rate of approximately 0.8 (Fig. 4A). As shown in Figure. 4B, low expression of Cav-1 in CAFs also predicted early recurrence of GC patients. Figure 4C and D indicated that tumor cells Cav-1 status had no significant correlation with overall survival and disease free survival (P = 0.178 and 0.104, respectively). Moreover, the cumulative 5 year survival rate of patients whose tumors exhibited high Cav-1 expression was 75.5% (95% CI, 0.642–0.868), whereas it was only 57.4% (95% CI, 0.436–0.692) in low Cav-1 expression subgroup (P = 0.053).

In univariate analysis, TNM stage, T stage, lymph node status and Cav-1 expression level were found to be significantly associated with the disease free survival of GC patients (P = 0.001, 0.003, 0.010 and 0.029, respectively; Table 4). TNM stage, T stage and Cav-1 expression level were significantly correlated with the overall survival (P = 0.012, 0.006, and 0.013, respectively; Table 4). To determine whether Cav-1 expression was an independent predictor of GC patients’ recurrence and survival, a multivariate...
Cav-1 in CAFs Predicts Outcome in Gastric Cancer
analysis was performed using COX proportional hazard regression model, together with age, T classification, TNM stage and other tumor features. Again, Cav-1 level in CAFs was independently and significantly associated with GC patients’ recurrence and outcome ($P = 0.034$ and $0.005$, respectively; Table 4). On the contrary, tumor cells Cav-1 level failed to prognosticate GC patient’s recurrence and survival in the simultaneous model (Table 4).

The death predictive value of Cav-1 thresholds in tumor cells and in CAFs was analyzed as well. As showed in Figure 5, Cav-1 level in CAFs predicted death with good performance; the area under the curve was 0.627 (95% CI: 0.515–0.738; $P = 0.032$). Whereas, Cav-1 level in tumor cells failed to predict death, with area under the curve of 0.551 (95% CI: 0.438–0.664; $P = 0.393$).

## Discussion

Here, we reported that Cav-1 immunoreactivity is mainly observed at the cell membrane and cytoplasm. In gastritis without IM tissues, Cav-1 signal is predominantly detected in the base and neck of fundic gland cells. In gastritis with IM tissues, Cav-1 staining mainly locates in the absorptive cell and goblet cell of metaplastic glands. This result correlates with another study which analyzed Cav-1 in gastric tissue via immunohistochemistry [27]. Cav-1 expression gradually decreases with the progression of GC and the expression level in CAFs rather than in tumor cells to a certain extent predicts recurrence and survival in GC patients.

Roles of Cav-1 protein in tumor development are tumor-dependent and compartment-dependent [12,30]. Cav-1 gene is localized to locus D7S522 of human chromosome 7q31.1, which is often deleted in some types of tumors [11]. Moreover, Cav-1 is implicated in the cavinol scaffolding domain and can induce inhibition of cytokine receptor signaling [14], suggesting the tumor suppressor role of Cav-1. The tumor promoting activity of Cav-1 has been widely confirmed by carefully detecting its expression levels and clinical values in varieties of cancers, such as tongue squamous cell carcinoma, esophageal squamous cell carcinoma, bladder transitional cell carcinomas, nasopharyngeal carcinoma and neck squamous cell carcinoma [16,31,32,33,34]. Cav-1 has different roles in tumor cells and stromal cells. For example, in breast and prostate cancer, loss of stromal Cav-1 but not tumor cells Cav-1 heralds poor prognosis [6,8,12,14], indicating the compartment-dependent roles of Cav-1.

Our results indicated that Cav-1 expression level in epithelia cells gradually decreased with the malignant progression of GC. Similar results were reported in another study [26] investigating Cav-1 expression of IM and GC, implying Cav-1 might be regarded as a tumor suppressor in the development of GC. Moreover, both tumor cells and CAFs Cav-1 protein expression status were not correlated to the typical clinicopathological parameters, such as T stage, TNM stage and Lauren classification. It was in contrast to the other study [26] which showed that the low expression of tumor cells Cav-1 protein was correlated with high T stage, TNM stage and lymph node metastasis. The difference might be due to the evaluation method: we evaluated the staining by multiplying the intensity and the proportion of cells stained and determined the cutoff point that had optimal sensitivity and specificity of the ROC curve based on overall survival status; whereas in the other research only the percentage of immunopositive cells was evaluated and the threshold of positive or negative was not presented. Besides, the larger sample size of our study influenced the results as well.

CAFs are among the most essential components of tumor stroma, with important functions inducing the deposition of ECM, regulating epithelial differentiation and inflammatory response and interacting with the microvasculature by secreting matrix metalloproteinases and vascular endothelial growth factor [35]. Since Cav-1 protein is the requisite structural component of caveolae, altered expression of Cav-1 protein in CAFs would impact various pathological processes and consequently promote tumor development. Loss of Cav-1 protein in CAFs promotes the activation of CAFs via activating TGF-β pathway, therefore facilitating the tumor microenvironment remodeling and tumor development [12]. However, another study published in Cell reported contrary functions of CAFs Cav-1 protein that stromal Cav-1 favors tumor invasion and metastasis through force-
dependent architectural regulation of the microenvironment [36]. Therefore, the role of CAFs Cav-1 remains uncertain. The results presented here demonstrated an independent prognostic predictor of GC involving the Cav-1 expression level in CAFs. Low expression of Cav-1 in CAFs but not in tumor cells independently prognosticated early recurrence and poor survival of GC patients. ROC analysis indicated the death predicting value of low Cav-1 in CAFs. The results implied the tumor inhibiting role of CAFs Cav-1 protein and were consistent with the finding in breast and prostate cancer, which elucidated that loss of stromal Cav-1 heralds poor prognosis [8,12,15]. Also, in breast cancer, it is clear that with the development of cancer, the tumor microenvironment becomes a hypoxic and ill-nutrition niche, stimulating autophagy in CAFs. Then the abnormal activated autophagy degrades Cav-1 in CAFs. Of course, whether similar mechanisms exist in GC requires more in vitro studies.

Furthermore, loss of stromal Cav-1 has great predictive value in ER (+), PR (+), HER2 (+), and the so-called triple-negative breast cancer patients (ER(-)/PR(-)/HER2(-)). Concurrently instituted endocrine therapy does not influence its predictive value, making it a new universal or widely applicable breast cancer prognostic marker [37]. GC is the fourth common and third death causing cancer in the world [38], which still lacks enough appropriate biomarkers for prognostic evaluation and personalized anti-cancer treatment. The HER2 positive GC patients are benefited from trastuzumab treatment, however, only a few patients are HER2 positive, for example, only 19% of GC patients showed HER2 positive in our study.

Table 3. Correlations between Cav-1 expression and clinicopathological parameters of gastric cancer.

| Parameters                  | Cav-1 in tumor cells | Cav-1 in CAFs |
|-----------------------------|----------------------|--------------|
|                             | n Low (%)            | High (%)     | P  | n Low (%) | High (%) | P  |
| Age                         |                      |              |    |           |          |    |
| <57                         | 131 122(93.1)        | 9(6.9)       | 0.824 | 112 64(57.1) | 48(42.9) | 0.371 |
| ≥57                         | 155 143(92.3)        | 12(7.7)      | 135 | 69(51.1)  | 66(48.9) | 0.157 |
| Gender                      |                      |              |    |           |          |    |
| Male                        | 205 191(93.2)        | 14(6.8)      | 0.618 | 178 101(56.7) | 77(43.3) | 0.157 |
| Female                      | 81 74(91.4)          | 7(8.6)       | 0.055 | 69 32(46.4)  | 37(53.6) | 0.890 |
| T stage                     |                      |              |    |           |          |    |
| T1+T2                       | 88 85(96.9)          | 3(3.1)       | 0.138 | 75 41(54.7)  | 34(45.3) | 0.090 |
| T3+T4                       | 198 180(90.9)        | 18(9.1)      | 172 | 92(53.5)  | 80(46.5) | 0.090 |
| Lymph node status           |                      |              |    |           |          |    |
| N0                          | 113 104(92.0)        | 9(8.0)       | 0.937 | 97 58(59.8)  | 39(60.2) | 0.321 |
| N1                          | 133 124(93.2)        | 9(6.8)       | 0.937 | 118 59(50.0) | 59(50.0) | 0.321 |
| N2                          | 40 37(92.5)          | 3(7.5)       | 0.937 | 32 16(50.0)  | 16(50.0) | 0.883 |
| TNM stage                   |                      |              |    |           |          |    |
| 0+Ia+Ib+II                  | 142 131(92.3)        | 11(7.7)      | 0.824 | 123 68(53.7) | 55(46.3) | 0.702 |
| IIa+IIb+IV                  | 144 134(93.1)        | 10(6.9)      | 0.824 | 124 65(52.4) | 59(47.6) | 0.702 |
| Grade of AC                 |                      |              |    |           |          |    |
| Well/Moderately             | 78 70(89.7)          | 8(10.3)      | 0.603 | 71 36(50.7)  | 35(49.3) | 0.118 |
| Poorly                      | 159 146(91.8)        | 13(8.2)      | 0.603 | 132 69(52.3) | 63(47.7) | 0.883 |
| Lauren classification       |                      |              |    |           |          |    |
| Intestinal-type             | 137 127(92.7)        | 10(7.3)      | 0.227 | 124 59(47.6) | 65(52.4) | 0.541 |
| Diffuse-type                | 123 116(94.3)        | 7(5.7)       | 0.227 | 101 62(61.4) | 39(38.6) | 0.541 |
| Mixed-type                  | 26 22(84.6)          | 4(15.4)      | 0.227 | 22 12(54.5)  | 10(45.5) | 0.541 |
| HER-2                       |                      |              |    |           |          |    |
| Negative                    | 145 131(90.3)        | 14(9.7)      | 0.740 | 131 76(58.0) | 55(42.0) | 0.541 |
| Positive                    | 34 32(94.1)          | 2(5.9)       | 0.740 | 30 15(50.0)  | 15(50.0) | 0.541 |
| Pathologic type             |                      |              |    |           |          |    |
| AC                          | 237 216(91.1)        | 21(8.9)      | 0.096 | 203 105(51.7) | 98(48.3) | 0.095 |
| Mucinous AC                 | 32 32(100.0)         | 0(0.0)       | 0.096 | 29 21(72.4)  | 8(27.6)  | 0.095 |
| UC                          | 17 17(100.0)         | 0(0.0)       | 0.096 | 15 7(46.7)  | 8(53.3)  | 0.095 |
| Cav-1 in tumor cells        |                      |              |    |           |          |    |
| Low (%)                     | 226 121(53.5)        | 105(46.5)    | 0.751 | 21 12(57.1)  | 9(42.9)  | 0.751 |
| High (%)                    |                      |              |    |           |          |    |

*TNM classification of malignant tumors (7th edition). AC, Adenocarcinoma; UC, Undifferentiated carcinoma.
doi:10.1371/journal.pone.0059102.t003
negative HER2 are still suffering from poor survival. Thus, identifying more targets that suppress GC development is highly needed. Herein, we demonstrated the values of using stromal proteins as biomarkers in GC, which might contribute to the molecular typing of GC and consequently the treatment of GC, verifying the essential roles of tumor stroma in tumor development. Moreover, a prospective study is highly recommended to validate the prognostic value and to investigate the clinical significance of detecting Cav-1 in CAFs.

One interesting thing is that although CAFs Cav-1 status can be used as a predictor, when the correlation between CAFs Cav-1 levels and classic clinicopathological parameters of GC were analyzed, no significant association was found. Thus, promoting tumor invasion and metastasis may not be the primary mechanisms by which loss of CAFs Cav-1 promotes GC development. Chemotherapy is the most common adjunctive therapy that are recommended to the middle and advanced stage GC patients in China. Combined with the results shown here, we highlighted that whether low expression of Cav-1 in CAFs correlated with chemotherapy resistance may be a notable problem deserving further study.

Finally, in our study, via the advanced QDs-based double immunofluorescent labeling technology, Cav-1 protein in CAFs was precisely located. The pseudo-color co-localization images permitted us to evaluate the Cav-1 level in CAFs exclusively, however, QDs-IHC and QDs-based double immunofluorescent labeling technology is not commonly used in clinical laboratories. Immunohistochemistry is the most commonly practiced technology in clinical laboratories. Our previous study manifests that QDs-IHC method is as sensitive and specific as IHC [22]. If you want to detect simultaneously two different proteins such as Cav-1 and α-SMA in one slide, QDs-based double labeling is a novel, reliable and alternative method, by which we can get the results as precise as possible.

**Conclusions**

In conclusion, our study evaluated the Cav-1 expression in both tumor cells and CAFs and investigated their clinical significance for GC patients. It is noteworthy that the expression of Cav-1 in CAFs rather than tumor cells particularly applicable in predicting early recurrence and poor survival prospects of GC patients, suggesting Cav-1 in CAFs may be a candidate therapeutic target.
and a useful prognostic marker of GC patients. Further studies are needed to investigate the mechanisms by which high levels of Cav-1 in CAFs suppress GC progression and, possibly, to develop therapeutics targeting Cav-1. Moreover, further clinical trials will be essential to verify the prognostic value of CAFs Cav-1 in GC and whether it could contribute to personalized anti-cancer treatment.

Acknowledgments

The authors thank Dr. Kathryn A Solka, Department of Biochemistry, Rush University Medical Center for writing assistance.

Author Contributions

Conceived and designed the experiments: XZ YH JG HC. Performed the experiments: XZ YH JG LF ZL GY HC. Analyzed the data: XZ YH JG ZL HC. Contributed reagents/materials/analysis tools: XZ YH JG ZL HC. Wrote the paper: XZ YH JG HC.

References

1. Dvorak HF, Weaver VM, Tlsty TD, Bergers G (2011) Tumor microenvironment and progression. J Surg Oncol 103: 468–474.
2. Mueller MM, Fusenig NE (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. Nature reviews Cancer 4: 839–849.
3. Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1: 46–54.
4. Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, et al. (2011) Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci 102: 1590–1596.
5. Simpkins SA, Hanby AM, Holliday DL, Spears V (2012) Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol 227: 490–496.

Table 4. COX proportional hazard models on disease free survival and overall survival of GC patients.

| Factors | Univariate analysis | Multivariate analysis |
|---------|---------------------|----------------------|
|         | P value | HR(95%CI) | P value | HR(95%CI) |
| Disease Free Survival | | | | |
| Sex (Male vs. Female) | 0.868 | 0.959(0.589,1.561) | | |
| Age (≤57 vs. ≥57) | 0.156 | 0.725(0.462,1.140) | 0.019 | 0.404(0.189,0.862) |
| TNM stage (I-II vs. III-IV) | 0.001 | 0.419(0.238,0.736) | 0.005 | 0.298(0.129,0.693) |
| T stage (T1-T2 vs. T3-T4) | 0.003 | 0.384(0.181,0.815) | | |
| Lymph node (No vs. Yes) | 0.010 | 0.474(0.248,0.907) | | |
| Lauren classification (Intestinal-type vs. Diffuse-type) | 0.886 | 1.036(0.639,1.681) | | |
| Grade of AC (Well and moderately vs. Poorly) | 0.738 | 0.914(0.535,1.560) | | |
| Cav-1 in CAFs (Low vs. High) | 0.029 | 1.694(1.034,2.775) | 0.034 | 2.188(1.063,4.504) |
| Cav-1 in tumor cells (Low vs. High) | 0.074 | 2.604(0.721,9.400) | | |
| Overall Survival | | | | |
| Sex (Male vs. Female) | 0.988 | 1.004(0.578,1.745) | | |
| Age (≤57 vs. ≥57) | 0.130 | 0.681(0.410,1.131) | 0.022 | 0.390(0.175,0.871) |
| TNM stage (I-II vs. III-IV) | 0.012 | 0.500(0.279,0.894) | | |
| T stage (T1-T2 vs. T3-T4) | 0.006 | 0.363(0.157,0.842) | 0.013 | 0.215(0.064,0.720) |
| Lymph node (No vs. Yes) | 0.061 | 0.558(0.288,1.081) | | |
| Lauren classification (Intestinal-type vs. Diffuse-type) | 0.759 | 0.923(0.552,1.543) | | |
| Grade of AC (Well and moderately vs. Poorly) | 0.886 | 0.965(0.595,1.565) | | |
| Cav-1 in CAFs (Low vs. High) | 0.013 | 1.966(1.183,3.456) | 0.005 | 3.236(1.427,7.353) |
| Cav-1 in tumor cells (Low vs. High) | 0.149 | 2.264(0.624,8.213) | | |

AC, Adenocarcinoma.

doi:10.1371/journal.pone.0059102.t004

Figure 5. ROC analysis of Cav-1 scores by overall survival of GC patients. The cutoffs of tumor cell and CAFs Cav-1 have optimal sensitivity and specificity. Cav-1 expression level in CAFs (area under the curve was 0.627, 95% CI: 0.515–0.738; P = 0.032); Cav-1 in tumor cells (area under the curve was 0.551, 95% CI: 0.438–0.664; P = 0.393).

doi:10.1371/journal.pone.0059102.g005
6. Wikiewicz AK, Dasgupta A, Sotija F, Mercier I, Pestell RG, et al. (2009) An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174: 2023–2034.
7. Paulsson J, Sjöblom T, Micke P, Ponten F, Landberg G, et al. (2009) Prognostic significance of stromal plakoglobin expression for pathogenic factor beta-receptor expression in human breast cancer. Am J Pathol 175: 334–341.
8. Di Vizio D, Morello M, Sotija F, Pestell RG, Freeman MR, et al. (2009) An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 8: 2420–2424.
9. Li M, Li C, Li D, Xie Y, Shi J, et al. (2012) Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma. Clinical & Experimental Metastasis 29: 865–877.
10. Adgey-Osypa PA, Rodriguez S, McLarty J (2010) Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma. Human Pathology 41: 1128–1137.
11. Engelman JA, Zhang XL, Galbiati F, Lisanti MP (1998) Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus 6q21.3. FEBS Lett 429: 330–336.
12. Sotgia F, Martinez-Outschoom UE, Howell A, Pestell RG, Pavlides S, et al. (2012) Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Ann Rev Pathol 7: 423–467.
13. Anderson RG (1998) The caveaslemembrane system. Annu Rev Biochem 67: 199–225.
14. Goetz JG, Lajoie P, Wiseman SM, Nabi IR (2008) Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 27: 715–733.
15. Sloan EK, Ciocca DR, Poulou N, Natoli A, Restall C, et al. (2009) Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 174: 2035–2043.
16. Xue J, Chen H, Diao L, Chen X, Xia D (2010) Expression of caveolin-1 in tongue squamous cell carcinoma by quantum dots. Eur J Histochem 54: 99–103.
17. Alliviatos AP (1996) Semiconductor Clusters, Nanocrystals, and Quantum Dots. Science 271: 937–943.
18. Li ZH, Peng J, Chen HL (2011) Biocomputated quantum dots as fluorescent probes for biomedicale imaging J Nanosci Nanotechnol 11: 7521–7526.
19. Chen C, Peng J, Xia HS, Yang GF, Wu QS, et al. (2009) Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials 30: 2912–2918.
20. Chen C, Sun SR, Gong YP, Qi CB, Peng CW, et al. (2011) Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2. Biomaterials 32: 7592–7599.
21. Liu XL, Peng CW, Chen C, Yang XQ, Hu MB, et al. (2011) Quantum dots-based double-color imaging of HER2 positive breast cancer invasion. Biochem Biophys Res Commun 409: 577–582.
22. Chen H, Xue J, Zhang Y, Zhu X, Gao J, et al. (2009) Comparison of quantum dots immunofluorescence histochemistry and conventional immunohistochemistry for the detection of caveolin-1 and PCNA in the lung cancer tissue microarray. J Mol Histol 40: 261–268.
23. Chen C, Peng J, Xia H, Wu Q, Zeng L, et al. (2010) Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity. Nanotechnology 21: 095101.
24. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schnabl P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844–847.
25. Li M, Chen H, Diao L, Zhang Y, Xia C, et al. (2010) Caveolin-1 and VEGF-C promote lymph node metastasis in the absence of intratumoral lymphangiogenesis in non-small cell lung cancer. Tumori 96: 734–743.
26. Sun Gy, Wu Jx, Wu Js, Fan Yt, Jin R (2012) Caveolin-1, E-cadherin and β-catenin in gastric carcinoma, precancerous tissues and chronic atrophic gastritis. Chinese J Cancer Res 24: 23–28.
27. Barresi V, Giuffre G, Vitarelli E, Todaro P, Tuccari G (2008) Caveolin-1 immuno-expression in human gastric cancer: histopathogenetic hypotheses. Virchows Arch 455: 571–578.
28. Burgermeister E, Xing X, Rocken C, Juhasz M, Chen J, et al. (2007) Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res 67: 8519–8528.
29. Barresi V, Cerassoli S, Paioli G, Vitarelli E, Giuffre G, et al. (2006) Caveolin-1 in meningiomas: expression and clinico-pathological correlations. Acta Neuro-pathol 112: 617–626.
30. Williams TM, Lisanti MP (2003) Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288: C494–506.
31. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, et al. (2002) Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94: 929–933.
32. Kunze E, Von Bonin F, Wernert C, Wundt M, Schlott T (2006) Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Int J Mol Med 17: 3–13.
33. Du ZM, Hu CF, Shao Q, Huang MY, Kou CW, et al. (2009) Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer 125: 1832–1841.
34. Zhang H, Su L, Muller S, Tighiouart M, Xu Z, et al. (2008) Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. Br J Cancer 99: 1684–1694.
35. Kalluri R, Zeiher M (2006) Fibroblasts in cancer. Nat Rev Cancer 6: 392–401.
36. Goetz JG, Minguet S, Navarro-Lezida I, Lazcano JJ, Samaniego R, et al. (2011) Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 146: 148–163.
37. Wikiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, et al. (2009) Towards a new “stromal-based” classification system for human breast cancer prognosis and therapy. Cell Cycle 8: 1654–1658.
38. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.